Please login to the form below

Not currently logged in
Email:
Password:

NOR-SWITCH

This page shows the latest NOR-SWITCH news and features for those working in and with pharma, biotech and healthcare.

Standing out in a crowd

Standing out in a crowd

explained. Switching. Once products reached the market Celltrion observed further challenges when it came to persuading physicians to switch patients from originator biologics to their biosimilar equivalents. ... This is despite work to study the effects

Latest news

  • Facing the new wave of biosimilars Facing the new wave of biosimilars

    One trial, the NOR-SWITCH study, has made a significant contribution to the evidence base for switching. ... Some policy makers have interpreted NOR-SWITCH results as confirmation of switching’s safety and efficacy.

  • Pfizer’s Remicade biosimilar receives Crohn's trial boost Pfizer’s Remicade biosimilar receives Crohn's trial boost

    In addition to existing data from the registration studies, real-world experience and the NOR-SWITCH trial, this data adds to the body of evidence supporting use of CT-P13 across ... That issue has already been studied to some extent in the NOR-SWITCH

  • NOR-SWITCH - the final piece in the biosimilar puzzle? NOR-SWITCH - the final piece in the biosimilar puzzle?

    that policymakers do not misinterpret or exaggerate the findings of the NOR-SWITCH trial. ... NOR-SWITCH is designed to evaluate the effects of a switch from the original biologic to a biosimilar.

  • Study finds no problems switching from Remicade to biosimilar Study finds no problems switching from Remicade to biosimilar

    The comparative trial - called NOR-SWITCH - was presented at the 2016 UEG Week in Vienna, Austria and showed that swapping from Remicade to a biosimilar version made by Celltrion posed no ... The data shows that safety and efficacy are maintained

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics